


NEUROSYS

 CNS/PNS IN VITRO
 DRUG DEVELOPMENT

From traditional use to standardized neuroprotective green-extract of *Huperzia serrata*

 30th International Symposium
 on the Chemistry of Natural Products

 Elnur GARAYEV, Laurent BOYER, Patricia FRANCON, Philippe POINDRON, Maud COMBES, Noelle CALLIZOT
 Neuro-Sys SAS, R&D Department, 410 Chemin Departemental 60, 13120 Gardanne, France

Corresponding author: elnur.garayev@neuro-sys.com

INTRODUCTION

Some plants belonging to the *Lycopodiaceae* species such as *Huperzia serrata* (Thunb.) Trevis (Fig. 1), *H. squarrosa* (Forst.) Trevis, *Lycopodium complanatum* L. and *L. cernua* (L.) Franco & Vasc have been used in Asiatic folk medicine for thousands of years to treat contusions, strains, schizophrenia and memory dysfunction [1, 2]. *H. serrata* and *H. saururus* are used respectively in Chinese and Argentinian folk medicine, via infusion, for their neuromuscular and memory-improving properties [3, 4].

Huperzine A, one of the constituents of *H. serrata*, was proven to be a reversible inhibitor of acetylcholinesterase with neuroprotective effects [5]. The results on more than 100,000 Chinese patients indicated that Huperzine A significantly improved cognitive functions [6] and had the potential to become an alternative treatment for Alzheimer's disease (AD). However, clinical trials with Huperzine A treatment also indicated that large doses of this molecule were needed to obtain significant effects in patients suffering from AD, thus increasing the occurrence of side effects [7].

Inspired by the traditional use (infusion/decoction), a standardized extract was obtained using a green extraction technique. This green extract has conserved original chemical profile of traditional preparation. The pharmacological activity was demonstrated with the synergistic effect of three compounds belonging to these extracts: Huperzine A (HA), Caffeic acid (CA) and Ferulic acid (FA) [8].


 Fig. 1 *Huperzia serrata* (Thunb.) Trevis

METHODS

Plant material: whole plant of wild *Huperzia serrata* was harvested in Vietnam in 2013. The plant was certified by Pr. Tran Hop and voucher specimen (TH000) was deposited in the laboratory of Neuro-Sys.

Extraction: traditional extract (TE) was prepared by boiling 10 g of grinded plant in 150 mL of water for 30 minutes. After filtration through cotton the filtrate was freeze dried. A microwave extractor Ethos X (Milestone, Italy) was used in the preparation of NSP01 (batch 005-E003a).

Chromatographical analysis was realized using Hitachi Chromaster Ultra RS system coupled to DAD detector. 0.1 % of formic acid in water and 0.1 % of formic acid in methanol were used as mobile phase. The separation was achieved on the Thermo Acclaim RSLC 120 C18 column (150 × 2.1 mm, 2.2 μm).

Pharmacological evaluation: Culture of cortical neurons: Primary rat cortical neurons were cultured as described by Callizot *et al.*, 2013 [9]. Briefly, pregnant females at 15 days of gestation were used. Cortex was dissociated then cells were centrifuged and resuspended in a defined culture medium. The cells were seeded at a density of 25,000 per well in poly-L-lysine pre-coated 96-well plates and cultured at 37 °C in an air (95 %)-CO₂ (5 %) incubator. The medium was changed every 2 days. On day 13 of culture, extract or compound and/or mix of compounds were solved in culture medium and pre-incubated for 1 hour before glutamate exposure. The cortical neurons were intoxicated with glutamate solution (40 μmol/L) for 20 min. After 20 min exposure, glutamate was washed out and fresh culture medium with extract or compound and/or mix of compounds was added for additional 48 hours.

Robotized platform (HCS system): End point evaluation: Neuron survival: 48 hours after intoxication, cortical neurons were stained with anti-MAP-2 antibody and revealed with Alexa Fluor IgG. Analysis of total number of neurons was performed automatically (30 randomly selected pictures per well; 20 × magnification). All data were expressed in percentage of control conditions (no intoxication, no glutamate = 100 %). All values expressed as mean ± SEM (standard error of the mean) (n = 6 wells per condition per culture). ANOVA followed by the Fisher's test when allowed.

RESULTS

A "Green" extract NSP01, obtained via microwave-assisted extraction, was compared to the TE. The superposition of chromatograms (Figure 2) showed comparable profiles for the two extracts. The content of Huperzine A was 0.21 % (m/m) in NSP01 vs 0.20 % (m/m) in the TE.






Fig. 2 Chromatograms (at 310 nm) of reference mix: Huperzine A (HA), Caffeic acid (CA) and Ferulic acid (FA) (black), traditional extract (blue) and NSP01 (green).

Pharmacological activity of TE and NSP01 extracts

Effect of TE (1 h pre-treatment) on neuron survival after glutamate injuries (40 μmol/L, 20 min)




Effect of NSP01 (1 h pre-treatment) on neuron survival after glutamate injuries (40 μmol/L, 20 min)




Discovery of synergistic effect of three compounds identified in TE and NSP01 extracts

Effect of HA/CA/FA (1 h pre-treatment) on neuron survival after glutamate injuries (40 μmol/L, 20 min)



Effect of mix of compounds (HA+CA+FA, 1 h pre-treatment) on neuron survival after glutamate injuries (40 μmol/L, 20 min)



M stands for mol/L
 * p < 0.05 vs. glutamate (one way ANOVA followed by Fisher's test)

↓ Non active concentrations of single compound on neuron survival

CONCLUSIONS

These results showed the similarity of chromatographical profile and of the content of active compound (HA) of NSP01 vs. TE.

The pharmacological activity of NSP01 lead to the discovery of synergistic activity between three compounds: Huperzine A, Caffeic acid and Ferulic acid. The active dose of Huperzine A was decreased from 1 nmol/L for a single compound to 10 pmol/L in a mix of three compounds. This synergistic activity should allow to decrease cholinergic side effects of high doses of Huperzine A.

Neuro-Sys is currently developing NSP01 as a food supplement for 2019.

References

- [1] X. Ma, C. Tan, D. Zhu, et D. R. Gang, « A survey of potential huperzine A natural resources in China: The Huperziaceae », *J. Ethnopharmacol.*, vol. 104, no 1-2, p. 54-67, March 2006.
- [2] N. N. Chuong, B. H. Trung, T. C. Luan, T. M. Hung, N. H. Dang, et N. T. Dat, « Anti-amnesic effect of alkaloid fraction from *Lycopodiella cernua* (L.) Pic. Serm. on scopolamine-induced memory impairment in mice », *Neurosci. Lett.*, vol. 575, p. 42-46, July, 2014.
- [3] D. Cuthbertson, J. Pilijac-Zegarac, et B. M. Lange, « Validation of a microscale extraction and high-throughput UHPLC-QTOF-MS analysis method for huperzine A in *Huperzia*: Microscale UHPLC-MS analysis of huperzine A », *Biomed. Chromatogr.*, vol. 26, no 10, p. 1191-1195, Oct. 2012.
- [4] M. G. Vallejo, J. A. Dimmer, M. G. Ortega, J. L. Cabrera, et A. M. Agnese, « Amino acid content and acetylcholinesterase inhibition of *Huperzia saururus* infusion and decoction », *Pharm. Biol.*, vol. 51, no 10, p. 1341-1345, Oct. 2013.
- [5] Liu, J.S., Zhu, Y.L., Yu, C.M., Zhou, Y.Z., Han, Y.Y., Wu, F.W., Qi, B.F., « The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity », *Canadian Journal of Chemistry* 64, 1986.
- [6] X. Ma, C. Tan, D. Zhu, et D. R. Gang, « A survey of potential huperzine A natural resources in China: The Huperziaceae », *J. Ethnopharmacol.*, vol. 104, no 1-2, p. 54-67, March 2006.
- [7] B. Wang, H. Wang, Z. Wei, Y. Song, L. Zhang, et H. Chen, « Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis », *J. Neural Transm.*, vol. 116, no 4, p. 457-465, Apr. 2009.
- [8] N. Callizot, « Combination composition comprising Huperzine », EP3106160A1, 15-June-2015.
- [9] N. Callizot, M. Combes, R. Steinschneider, et P. Poindron, « Operational dissection of β-amyloid cytopathic effects on cultured neurons », *J. Neurosci. Res.*, vol. 91, no 5, p. 706-716, March 2013.